Showing 741 - 760 results of 1,354 for search '(( significant decrease decrease ) OR ( significantly impairs decrease ))~', query time: 0.45s Refine Results
  1. 741
  2. 742

    Oligos used in this study. by Yanfeng Li (113424)

    Published 2025
    “…RNF213 deficiency impairs type I interferon (IFN-I) production and decreases the expression of interferon-stimulated genes (ISGs) in response to IFN-β stimulation and <i>Acinetobacter baumannii</i> infection. …”
  3. 743
  4. 744

    SPIRIT Schedule of Enrollment. by Asma Salari (21432948)

    Published 2025
    “…</p><p>Results</p><p>The EX group showed increased EMG activation for the tibialis anterior, gastrocnemius medialis, rectus femoris, and biceps femoris in both anterior-posterior (2.23 MVIC%, 95% CI: 1.13 to 3.34, p < 0.001) and posterior-anterior directions (2.35 MVIC%, 95% CI: 1.80 to 2.91, p < 0.001) compared to CO group. Onset time decreased significantly in the EX group relative to CO group (anterior-posterior: -108.07 ms, 95% CI: -117.23 to -98.89, p < 0.001; posterior-anterior: -98.72 ms, 95% CI: -106.54 to -90.90, p < 0.001). …”
  5. 745

    Measuring muscle strength [49]. by Asma Salari (21432948)

    Published 2025
    “…</p><p>Results</p><p>The EX group showed increased EMG activation for the tibialis anterior, gastrocnemius medialis, rectus femoris, and biceps femoris in both anterior-posterior (2.23 MVIC%, 95% CI: 1.13 to 3.34, p < 0.001) and posterior-anterior directions (2.35 MVIC%, 95% CI: 1.80 to 2.91, p < 0.001) compared to CO group. Onset time decreased significantly in the EX group relative to CO group (anterior-posterior: -108.07 ms, 95% CI: -117.23 to -98.89, p < 0.001; posterior-anterior: -98.72 ms, 95% CI: -106.54 to -90.90, p < 0.001). …”
  6. 746

    Details of aquatic exercise protocol. by Asma Salari (21432948)

    Published 2025
    “…</p><p>Results</p><p>The EX group showed increased EMG activation for the tibialis anterior, gastrocnemius medialis, rectus femoris, and biceps femoris in both anterior-posterior (2.23 MVIC%, 95% CI: 1.13 to 3.34, p < 0.001) and posterior-anterior directions (2.35 MVIC%, 95% CI: 1.80 to 2.91, p < 0.001) compared to CO group. Onset time decreased significantly in the EX group relative to CO group (anterior-posterior: -108.07 ms, 95% CI: -117.23 to -98.89, p < 0.001; posterior-anterior: -98.72 ms, 95% CI: -106.54 to -90.90, p < 0.001). …”
  7. 747

    Healthy control group HR and CBF changes. by Liuchuang Wei (19273099)

    Published 2025
    “…<div><p>Postural Orthostatic Tachycardia Syndrome is characterized by an excessive increase in heart rate during postural changes without significant blood pressure alterations, often accompanied by symptoms such as dizziness, fatigue, and palpitations. …”
  8. 748

    List of abbreviations used in this paper. by Liuchuang Wei (19273099)

    Published 2025
    “…<div><p>Postural Orthostatic Tachycardia Syndrome is characterized by an excessive increase in heart rate during postural changes without significant blood pressure alterations, often accompanied by symptoms such as dizziness, fatigue, and palpitations. …”
  9. 749

    Estimation of the CO and CBF. by Liuchuang Wei (19273099)

    Published 2025
    “…<div><p>Postural Orthostatic Tachycardia Syndrome is characterized by an excessive increase in heart rate during postural changes without significant blood pressure alterations, often accompanied by symptoms such as dizziness, fatigue, and palpitations. …”
  10. 750
  11. 751
  12. 752

    Adverse event list. by Stefan Halbherr (21353882)

    Published 2025
    “…</p><p>Non-motor symptoms of PD, motor parkinsonian signs off medication, and quality of life improved significantly during the treatment phase, including the MDS-UPDRS total score (mean decrease −11.09; 95% Confidence Interval [CI]; −18, −4.1; <i>p</i> = 0.006), the Parkinson’s disease Questionnaire-39 (PDQ-39) summary index (mean decrease −2.91; 95% CI; −4.4, −1.4; <i>p</i> = 0.005), and the Non-Motor Symptoms Questionnaire (NMS-Quest) (mean decrease −4.27; 95% CI; −6.5, −2.1; <i>p</i> = 0.009). …”
  13. 753

    Patient characteristics. by Stefan Halbherr (21353882)

    Published 2025
    “…</p><p>Non-motor symptoms of PD, motor parkinsonian signs off medication, and quality of life improved significantly during the treatment phase, including the MDS-UPDRS total score (mean decrease −11.09; 95% Confidence Interval [CI]; −18, −4.1; <i>p</i> = 0.006), the Parkinson’s disease Questionnaire-39 (PDQ-39) summary index (mean decrease −2.91; 95% CI; −4.4, −1.4; <i>p</i> = 0.005), and the Non-Motor Symptoms Questionnaire (NMS-Quest) (mean decrease −4.27; 95% CI; −6.5, −2.1; <i>p</i> = 0.009). …”
  14. 754

    Resveratrol-Loaded PLGA Enhanced Vitrified Oocyte Viability through Rab11fip4/Arf5-Mediated Internalization Route by Yixiao Zhu (9870701)

    Published 2025
    “…Knockdown of Rab11fip4 significantly impaired oocyte maturation and nanoparticles internalization. …”
  15. 755

    Resveratrol-Loaded PLGA Enhanced Vitrified Oocyte Viability through Rab11fip4/Arf5-Mediated Internalization Route by Yixiao Zhu (9870701)

    Published 2025
    “…Knockdown of Rab11fip4 significantly impaired oocyte maturation and nanoparticles internalization. …”
  16. 756

    Resveratrol-Loaded PLGA Enhanced Vitrified Oocyte Viability through Rab11fip4/Arf5-Mediated Internalization Route by Yixiao Zhu (9870701)

    Published 2025
    “…Knockdown of Rab11fip4 significantly impaired oocyte maturation and nanoparticles internalization. …”
  17. 757
  18. 758

    Minimal data set. by Fu-Lin Yu (21446056)

    Published 2025
    “…Prolonged and excessive exposure to arsenic causes various toxic reactions, leading to diseases that significantly impact health and lifespan. Increasing evidence suggests that arsenic damages skeletal muscle tissue by reducing muscle mass and causing atrophy, thereby contributing to conditions such as respiratory and cardiovascular diseases, as well as diabetes. …”
  19. 759
  20. 760